NASDAQ:TLC - Taiwan Liposome Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.00
+0 (0.00%)
Get New Taiwan Liposome Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Taiwan Liposome in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.00.

This chart shows the closing price for TLC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Taiwan Liposome. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/13/2021HC WainwrightDowngradeBuy ➝ Neutral$11.00 ➝ $7.50Medium
7/7/2021LaidlawDowngradeBuy ➝ HoldHigh
10/29/2020Cantor FitzgeraldReiterated RatingOverweightLow
10/29/2020HC WainwrightReiterated RatingBuyHigh
8/17/2020HC WainwrightReiterated RatingBuy$11.00Medium
6/1/2020Cantor FitzgeraldBoost Price TargetOverweight$10.00 ➝ $12.00High
2/13/2020HC WainwrightReiterated RatingBuy$11.00Medium
2/12/2020Cantor FitzgeraldLower Price TargetOverweight$11.00 ➝ $10.00Low
12/23/2019Cantor FitzgeraldInitiated CoverageOverweight$11.00Low
10/23/2019HC WainwrightReiterated RatingBuy$10.00Low
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
9/24/2019HC WainwrightSet Price TargetBuy$10.00Medium
6/20/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformLow
5/20/2019HC WainwrightReiterated RatingBuy$10.00Low
4/18/2019HC WainwrightReiterated RatingBuyLow
4/5/2019Cantor FitzgeraldSet Price TargetBuy$11.00Low
3/18/2019Cantor FitzgeraldReiterated RatingBuy$11.00Low
12/27/2018Cantor FitzgeraldInitiated CoverageOverweight$11.00High
12/17/2018LaidlawInitiated CoverageBuy ➝ Buy$11.00Low
12/17/2018Janney Montgomery ScottInitiated CoverageBuy ➝ BuyLow
12/17/2018HC WainwrightInitiated CoverageBuy ➝ Buy$9.00Low
(Data available from 8/10/2017 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/12/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Taiwan Liposome logo
Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.
Read More

Today's Range

Now: $7.00
Low: $7.00
High: $7.00

50 Day Range

MA: $7.10
Low: $6.76
High: $7.63

52 Week Range

Now: $7.00
Low: $4.07
High: $7.70

Volume

12,400 shs

Average Volume

133,095 shs

Market Capitalization

$294.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Taiwan Liposome?

The following equities research analysts have issued stock ratings on Taiwan Liposome in the last year:
View the latest analyst ratings for TLC.

What is the current price target for Taiwan Liposome?

0 Wall Street analysts have set twelve-month price targets for Taiwan Liposome in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Taiwan Liposome in the next year.
View the latest price targets for TLC.

What is the current consensus analyst rating for Taiwan Liposome?

Taiwan Liposome currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TLC.

What other companies compete with Taiwan Liposome?

How do I contact Taiwan Liposome's investor relations team?

Taiwan Liposome's physical mailing address is 11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company's listed phone number is 886226557377 and its investor relations email address is [email protected] The official website for Taiwan Liposome is www.tlcbio.com. Learn More about contacing Taiwan Liposome investor relations.